Cargando…

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy

PURPOSE: We evaluated the 2-year efficacy of combined intravitreal ranibizumab (IVR) treatment and photodynamic therapy (PDT) for treatment-naïve polypoidal choroidal vasculopathy (PCV). PATIENTS AND METHODS: Twenty-two eyes of 22 Japanese patients with treatment-naïve PCV were prospectively recruit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nemoto, Rei, Miura, Masahiro, Iwasaki, Takuya, Goto, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474272/ https://www.ncbi.nlm.nih.gov/pubmed/23109800 http://dx.doi.org/10.2147/OPTH.S37252

Ejemplares similares

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
por: Wong, Ian Y., et al.
Publicado: (2015)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
por: Sakurai, Madoka, et al.
Publicado: (2014)

Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy
por: Ito, Arisa, et al.
Publicado: (2020)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019)

Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
por: Lai, Kunbei, et al.
Publicado: (2018)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Disadvantages of photodynamic therapy for polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar
Publicado: (2010)

Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports
por: Iesato, Yasuhiro, et al.
Publicado: (2018)

Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy
por: Liu, Ling, et al.
Publicado: (2015)

Photodynamic therapy for polypoidal choroidal vasculopathy secondary to choroidal nevus
por: Wong, James G, et al.
Publicado: (2017)

Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
por: Ma, I-Hsin, et al.
Publicado: (2021)

Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up
por: Romano, Mario R, et al.
Publicado: (2010)

One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
por: Medina-Baena, Marta, et al.
Publicado: (2018)

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
por: Lim, Tock H., et al.
Publicado: (2020)

Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy
por: Azuma, Keiko, et al.
Publicado: (2020)

Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
por: Liu, Siyin, et al.
Publicado: (2022)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
por: Wong, James G., et al.
Publicado: (2017)

Author reply to comment on photodynamic therapy and polypoidal choroidal vasculopathy
por: Williams, Gwyn Samuel, et al.
Publicado: (2014)

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy
por: Hikichi, Taiichi, et al.
Publicado: (2013)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Efficacy of Initial vs. Delayed Photodynamic Therapy in Combination With Conbercept for Polypoidal Choroidal Vasculopathy
por: Sun, Zuhua, et al.
Publicado: (2022)

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy
por: Nishide, Tadayuki, et al.
Publicado: (2013)

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
por: Jeon, Young-Joon, et al.
Publicado: (2021)

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi, Kanji, et al.
Publicado: (2018)

Polypoidal Choroidal Vasculopathy in Asians
por: Wong, Chee Wai, et al.
Publicado: (2015)

One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
por: Weng, Hsin-Yu, et al.
Publicado: (2019)

Corrigendum: Efficacy of Initial vs. Delayed Photodynamic Therapy in Combination With Conbercept for Polypoidal Choroidal Vasculopathy
por: Sun, Zuhua, et al.
Publicado: (2022)

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
por: Cho, Han Joo, et al.
Publicado: (2012)

Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy
por: Hikichi, Taiichi, et al.
Publicado: (2016)

Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy
por: Hikichi, Taiichi
Publicado: (2015)

Choroidal Nevus in an Eye with Polypoidal Choroidal Vasculopathy
por: Asao, Kazunobu, et al.
Publicado: (2014)

Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy
por: Ho, Mary, et al.
Publicado: (2016)

Long-Term Prognosis of Patients with Polypoidal Choroidal Vasculopathy Treated with Photodynamic Therapy
por: Sakaeda, Yukinori, et al.
Publicado: (2023)

Choroidal excavation with polypoidal choroidal vasculopathy: a case report
por: Kobayashi, Wataru, et al.
Publicado: (2012)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ahdvqmuhkbs1togsghonsrmu7